Mikami Koji Department
Hyogo Medical University(Specialty Division)
, Clinical Medicine Seminars
Hyogo Medical University(Specialty Division)
Thoracic Oncology, Clinical Medicine Seminars
Position
■ Journal
1.
Original article
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. 2013/09
2.
Original article
Clinical significance of serum angiopoietin-1 in malignant peritoneal mesothelioma. 2013/10
3.
Original article
Recurrence of Lung Adenocarcinoma After an Interval of 15 Years Revealed by Demonstration of the Same Type of EML4-ALK Fusion Gene 2014/08
4.
Original article
Naftopidil Is Useful for the Treatment of Malignant Pleural Mesothelioma 2014/10
5.
Introduction
Challenges for the development of immunotherapy in small-cell lung cancer. 2018/06
6.
Case report
Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report. 2018/08
7.
Original article
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma. 2018/09
8.
Original article
Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies. 2021/12
AMP Converted from Intracelluarly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis (Poster presentation,General Lecture) 2013/10/29
2.
Clinical role of pleural effusion ADA levels in malignant pleural mesothelioma (Poster presentation,General Lecture) 2014/10/22
3.
Postoperative chemotherapy after pleurectomy/decortication for malignant pleural mesothelioma (Poster presentation,General Lecture) 2014/10/22
4.
Naftopidil Is Effective in the Treatment of Malignant Pleural Mesothelioma. (Poster presentation,General Lecture) 2015/09/09
5.
NF2 mutations in malignant pleural mesothelioma synchronous with acoustic neuroma:disease-causing mutation or chance effect? (Oral presentation,General Lecture) 2015/09/09
6.
A report on three cases of intramuscular metastasis from malignant pleural mesothelioma (Poster presentation,General Lecture) 2015/12/20
7.
Examination of the serum soluble mesothelin-related peptide (SMRP) level in patients with malignant pleural mesothelioma (Poster presentation,General Lecture) 2016/05/02
8.
Patterns of Detectable Tumor Progression in Patients with Malignant Pleural Mesothelioma with an FDG-PET-Negative T1a Tumor (Poster presentation,General Lecture) 2016/05/02
9.
Relationship between Histological Type and Pleural Mesothelioma (Poster presentation,General Lecture) 2016/05/02
10.
PET/CT FOR PATIENTS WITH VERY EARLY CLINICAL STAGE OF MALIGNANT PLEURAL MESOTHELIOMA:WHEN CAT PET/CT DETECT TUMOR GROWTH OF TO/T1A MESOTHLIOMA? (Poster presentation,General Lecture) 2016/12/06
11.
between the stainability of the neurofibromatosis type 2 gene-related protein merlin and the tumor properties of mesotheliomas (Poster presentation,General Lecture) 2016/12/07
12.
Mesothelium Covering Pleural Plaque Is Not Primary Involved in Asbestos-Induced Mesothelial Carcinogenesis in Human (Poster presentation,General Lecture) 2016/12/07
13.
Cisplatin in Combination for Pemetrexed in the Treatment of Patients with Advanced Malignant Peritoneal Mesothelioma -Retrospective study of 24 cases (Poster presentation,General Lecture) 2016/12/16
14.
Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab (Poster presentation,General Lecture) 2018/09/24